(Q34719632)

English

Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies (English)

1 reference

Europe PubMed Central

4 August 2017

11

object named as

Hervé Bazin

0 references

Thierry Chardès

object named as

Thierry Chardès

8

0 references

Caroline Bascoul-Mollevi

5

object named as

Caroline Bascoul-Mollevi

1 reference

Europe PubMed Central

4 August 2017

7

object named as

David Azria

1 reference

Europe PubMed Central

4 August 2017

author name string

Nadège Gaborit

1

1 reference

Europe PubMed Central

4 August 2017

Christel Larbouret

2

1 reference

Europe PubMed Central

4 August 2017

Julie Vallaghe

3

1 reference

Europe PubMed Central

4 August 2017

Frédéric Peyrusson

4

1 reference

Europe PubMed Central

4 August 2017

Evelyne Crapez

6

1 reference

Europe PubMed Central

4 August 2017

Marie-Alix Poul

9

1 reference

Europe PubMed Central

4 August 2017

Gérard Mathis

10

1 reference

Europe PubMed Central

4 August 2017

André Pèlegrin

12

1 reference

Europe PubMed Central

4 August 2017

language of work or name

0 references

publication date

31 January 2011

1 reference

Europe PubMed Central

4 August 2017

Journal of Biological Chemistry

1 reference

Europe PubMed Central

4 August 2017

286

1 reference

Europe PubMed Central

4 August 2017

13

1 reference

Europe PubMed Central

4 August 2017

11337-11345

1 reference

Europe PubMed Central

4 August 2017

describes a project that uses

monoclonal antibody

1 reference

based on heuristic

inferred from title

Kinase-mediated quasi-dimers of EGFR

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

A proximity ligation assay using transiently transfected, epitope-tagged proteins: application for in situ detection of dimerized receptor tyrosine kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

EGFR signaling and drug discovery.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

HER-dimerization inhibitors: evaluating pertuzumab in women's cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

ErbB receptors and signaling pathways in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Interaction of antibodies with ErbB receptor extracellular regions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

EGFR family: structure physiology signalling and therapeutic targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

A quantitative analysis of kinase inhibitor selectivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Monoclonal antibodies as therapeutic agents for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Effect of ErbB2 coexpression on the kinetic interactions of epidermal growth factor with its receptor in intact cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Untangling the ErbB signalling network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064190

7 July 2018

EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.223503

21 January 2018

Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.223503

21 January 2018

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.223503

21 January 2018

A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.223503

21 January 2018

Cell surface detection of membrane protein interaction with homogeneous time-resolved fluorescence resonance energy transfer technology

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.223503

21 January 2018

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.223503

21 January 2018

Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.223503

21 January 2018

Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer Is Rare

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.223503

21 January 2018

Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization

1 reference

https://pubmed.ncbi.nlm.nih.gov/21282108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1074/JBC.M111.223503

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34719632&oldid=2034249130"